Table 1.
Baseline characteristics
| First author | Year | Phase | Histology | RB assessment (Biomarkers) | Treatment | Dose | Number | Age (median) | Gender M/F | Region |
|---|---|---|---|---|---|---|---|---|---|---|
| Cristofanilli M | 2016 | III | ER+, HER2‐, advanced BC | NR | Palbociclib‐Fulvestrant vs Placebo‐Fulvestrant | 125 mg | 521 (347/174) | 57 (57/56) | 0 + 521 | 17 countries |
| Finn RS | 2016 | II | ER+, HER2‐, advanced BC | NR | Palbociclib‐Letrozole vs Placebo‐Letrozole | 125 mg | 666 (444/222) | 62/61 | 0 + 666 | 17 countries |
| Finn RS | 2015 | II | ER+, HER2‐, advanced BC | NR | Palbociclib‐Letrozole vs Letrozole | 125 mg | 165 (84/81) | 63/64 | 0 + 165 | USA |
| Tamura K | 2016 | I | ER+, HER2‐, advanced BC | NR | Palbociclib | 125 mg | 12 | 55 (24‐76) | 0 + 12 | Japan |
| DeMichele A | 2014 | II | Metastatic or Advanced BC | IHC (Antibody of MS‐107‐P, clone 1F8) | Palbociclib | 125 mg | 37 | 59 (39‐88) | 0 + 37 | USA |
| Dickson MA | 2013 | II | Advanced or metastatic WDLS/DDLS | IHC (RB [4H1] mouse monoclonal antibody) | Palbociclib | 200 mg | 30 | 65 (37‐83) | 16 + 14 | USA |
| Flaherty KT | 2012 | I | Advanced solid tumors | IHC | Palbociclib | Dose finding | 41 | 54 (22‐77) | 20 + 21 | USA |
| Schwartz GK | 2011 | I | Rb‐positive advanced solid tumors or NHL | NR | Palbociclib | Dose finding 100/150/200/225 mg | 33 | 63 (35‐78) | 16 + 17 | USA |
| Vaughn DJ | 2015 | II | Metastatic GCTs | IHC (RB1 mouse monoclonal antibody) | Palbociclib | 125 mg | 29 | 31 (17‐56) | 26 + 4 | USA |
BC, breast cancer; GCTs, germ cell tumors; IHC, immunohistochemistry; NHL, non‐Hodgkin's lymphoma; NR, not report; WDLS/DDLS, well‐differentiated or dedifferentiated liposarcoma.